Skip to main content
Loading

Opening Address & Keynote Presentation by Ablexis and AlivaMab Biologics. Driven by Diversity: AlivaMab® Platforms Fuel Biologics Discovery for Complex Targets

17 Jun 2024
Salon H
Bi/Multispecifics , Emerging Technologies , Formats & Scaffolds , Lead Identification & Optimization , Target Selection
Opening Address & Keynote Presentation by Ablexis and AlivaMab Biologics. Driven by Diversity: AlivaMab® Platforms Fuel Biologics Discovery for Complex Targets

Successful biologics development hinges on innovative strategies for generating diversity in antibody discovery. With an ever-growing suite of AlivaMab® Mouse strains and creative ‘fit-for-purpose’ strategies, Ablexis and AlivaMab Biologics are delivering diverse panels of lead-quality antibodies. Here, we will highlight how diverse AlivaMab Mouse strains and discovery processes enable successful discovery of diverse panels for CLC, human single-domain, membrane multispanners, CD3, and TCRm antibodies.

Industry Expert
Jane Seagal, Vice President, Antibody Discovery - Ablexis and AlivaMab Biologics